Navigation Links
Boston Scientific Second Quarter Results Exceed Consensus Sales and EPS; Full-Year Guidance Raised
Date:7/28/2011

perations. Management believes this is a critical metric for the Company in measuring the Company's ability to generate cash and pay down debt. Therefore, amortization expense is excluded from management's assessment of operating performance and is also excluded from the measures management uses to set employee compensation. Accordingly, management has excluded amortization expense for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of the Company's current operating performance, particularly in terms of liquidity.

Regional and Divisional Revenue Growth Rates Excluding the Impact of Changes in Foreign Currency Exchange Rates

Changes in foreign currency exchange rates - The impact of changes in foreign currency exchange rates is highly variable and difficult to predict. Accordingly, management excludes the impact of changes in foreign currency exchange rates for purposes of reviewing regional and divisional revenue growth rates to facilitate an evaluation of the Company's current operating performance and comparison to the Company's past operating performance.

Adjusted Free Cash Flow

Capital expenditures - This adjustment represents additions to property, plant and equipment necessary to fund the Company's future growth. The Company adjusts its cash generated from operations by these recurring expenditures, as management believes this measurement to be useful as an indicator of the Company's ability to service its debt, meet other payment obligations and make strategic acquisitions and fund other corporate initiatives. Accordingly, management included these payments to facilitate an evaluation of the Company's current operating performance and comparison to the Company's past operating performance.

Restructuring payments - This adjustment represents cash payments associated primarily with severance, costs to transfer production lines from one facility to another and
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine technology :

1. Boston Scientific Announces Five-Year, $150 Million Investment in China to Accelerate Commercial Expansion
2. Boston Scientific to Webcast Conference Call Discussing Second Quarter 2011 Financial Results
3. Boston Scientific Completes Clinical Trial Enrollment for Adapt™ Monorail™ Carotid Stent System
4. Boston Scientific Announces U.S. and European Launch of Interlock™ - 35 Fibered IDC™ Occlusion System
5. Boston Scientific Welcomes Passage of Patent Reform Bill
6. Boston Scientific to Donate $1 Million to ASGEs IT & T Capital Campaign to Build a New State-of-the-Art GI Training Center
7. Boston Scientific Announces Global Launch of Mustang™ PTA Balloon Catheter
8. Boston Scientific Announces Favorable Appellate Court Ruling Affirming Invalidity of J&J Patents
9. Boston Scientific Announces Voluntary Recall of iCross™ Coronary Imaging Catheters
10. Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System
11. Boston Heart Lab Changes Name to Boston Heart Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... MiMedx Group, Inc. (OTC Bulletin Board: MDXG.OB) announced today ... Shield(TM). In April 2009, The Food and Drug Administration ... vessels following anterior vertebral surgeries. The Vaso Shield is ... and patent applications, as well as a proprietary manufacturing process. ...
... Sciences, Inc., a privately held biopharmaceutical company that specializes in ... reported top-line results from the month 24 readout of the ... Phase 3 pivotal clinical trials (Trial A and Trial B) ... macular edema (DME). The primary efficacy endpoint for the FAME ...
Cached Medicine Technology:MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device 2MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device 3Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 2Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 3Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 4Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 5Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 6
(Date:4/18/2014)... The Gerontologist reports that among ... a decrease in anxiety about death and increases in ... lives. In particular, listening to gospel music is associated ... increase in sense of control. , These associations are ... individuals of both low- and high-socioeconomic status. , The ...
(Date:4/18/2014)... Medicine researchers have been awarded two-year grants for their ... this month. Of the 110 initial submissions to the ... Program, only four projects were funded, three of which ... Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and Elias ... of oncology, will use his $500,000 proof of principle ...
(Date:4/18/2014)... 2014) Benaroya Research Institute at Virginia Mason (BRI) ... particular molecule in metastatic breast cancer reduces both the ... metastases. BRI scientists have found in models of the ... 60 - 80 percent and can keep the tumor ... million five-year grant comes from the National Cancer Institute ...
(Date:4/18/2014)... (April 18, 2014) ― A new study in the ... patterns in health-related Google searches reveals a recurring pattern ... , Investigators from San Diego State University, ... Monday Campaigns, analyzed "healthy" Google searches (searches that included ... diet") originating in the U.S. from 2005 to 2012. ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2
... probability of tumor response ... and accelerates drug development, SEATTLE, Oct. ... Systems Medicine, LLC (SM), a,wholly-owned subsidiary of CTI, today announced ... trial of brostallicin used in combination,with either bevacizumab or irinotecan, ...
... results include 19 percent sales growth and EPS of $.85, Q3 pro forma adjusted results ... ... EPS guidance updated to $3.50 - $3.55, or ... $2.76 - $2.81 reported, INDIANAPOLIS, Oct. 18 Eli Lilly and Company,(NYSE: LLY ) ...
... Consecutive Quarter, DEERFIELD, Ill., Oct. 18 Baxter ... results for the period,ended September 30, 2007 and raised ... quarter net income of $395 million increased 6 percent ... 2006. Net earnings per,diluted share of $0.61 increased 7 ...
... Blood Pressure Cuff and Weight Scale Added to Our ... Telemedicine Product ... Sheets: XMDC) announced the company has added two new,Bluetooth(R) enabled telemedicine ... care, hospitals, long term care,facilities, and physician groups. "The addition ...
... More than half of holiday shoppers (57,percent) plan ... good cause*. This,year, choose a gift that will brighten ... the seventh leading cause of death,in the United States. ... families struggling with,Alzheimer,s or support innovative research grants, which ...
... Inc. (NASDAQ:QLTI;,TSX:QLT) today reported that Novartis AG announced ... million for the quarter ended,September 30, 2007. This ... the,third quarter of 2006 and a 17.9% decline ... in the U.S. for the quarter were approximately ...
Cached Medicine News:Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 2Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 3Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 4Health News:Lilly Delivers Strong Third-Quarter Results 2Health News:Lilly Delivers Strong Third-Quarter Results 3Health News:Lilly Delivers Strong Third-Quarter Results 4Health News:Lilly Delivers Strong Third-Quarter Results 5Health News:Lilly Delivers Strong Third-Quarter Results 6Health News:Lilly Delivers Strong Third-Quarter Results 7Health News:Lilly Delivers Strong Third-Quarter Results 8Health News:Lilly Delivers Strong Third-Quarter Results 9Health News:Lilly Delivers Strong Third-Quarter Results 10Health News:Lilly Delivers Strong Third-Quarter Results 11Health News:Lilly Delivers Strong Third-Quarter Results 12Health News:Lilly Delivers Strong Third-Quarter Results 13Health News:Lilly Delivers Strong Third-Quarter Results 14Health News:Lilly Delivers Strong Third-Quarter Results 15Health News:Lilly Delivers Strong Third-Quarter Results 16Health News:Lilly Delivers Strong Third-Quarter Results 17Health News:Lilly Delivers Strong Third-Quarter Results 18Health News:Lilly Delivers Strong Third-Quarter Results 19Health News:Baxter Reports Strong Third Quarter Sales and Earnings 2Health News:Baxter Reports Strong Third Quarter Sales and Earnings 3Health News:Baxter Reports Strong Third Quarter Sales and Earnings 4Health News:Baxter Reports Strong Third Quarter Sales and Earnings 5Health News:Baxter Reports Strong Third Quarter Sales and Earnings 6Health News:Baxter Reports Strong Third Quarter Sales and Earnings 7Health News:Baxter Reports Strong Third Quarter Sales and Earnings 8Health News:Baxter Reports Strong Third Quarter Sales and Earnings 9Health News:Baxter Reports Strong Third Quarter Sales and Earnings 10Health News:Baxter Reports Strong Third Quarter Sales and Earnings 11Health News:Baxter Reports Strong Third Quarter Sales and Earnings 12Health News:Baxter Reports Strong Third Quarter Sales and Earnings 13Health News:Baxter Reports Strong Third Quarter Sales and Earnings 14Health News:Baxter Reports Strong Third Quarter Sales and Earnings 15
Equinox is a truly unique approach to cosmetic enhancement contact lenses and is worn as a conventional wear lens....
... QuantiGene 2.0 is a reagent and ... expression knockdown. The high throughput plate based ... assay that provides a unique approach for ... reporter signal using branched DNA (bDNA) technology. ...
Xsera Rapid HIV-1/2 Antibody Controls are unassayed positive and negative quality control materials used for monitoring the performance of qualitative rapid HIV-1 and HIV-2 test kits....
...
Medicine Products: